The Prognostic Impact of Symptoms and Lesion Depth in Partial Removal of Carious Tissue
Launched by UNIVERSITY OF HELSINKI · Apr 15, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how certain factors, like symptoms and the depth of tooth decay, can affect the success of a common dental treatment called partial removal of carious tissue. This treatment is often used for adults with deep cavities in their back teeth (premolars and molars). The study aims to find out if having symptoms before the procedure or how deep the cavity is makes a difference in how well the tooth heals afterward.
To participate, individuals need to be adults aged between 18 and 62 who can communicate in Finnish or English and have a specific type of deep cavity that isn’t causing severe pain. Participants will undergo the standard treatment and then fill out a questionnaire about their symptoms a week later. Their teeth will be monitored for 12 to 24 months to see how they respond. It’s important to note that participants need to meet certain health criteria to be eligible, and those with specific dental issues or health conditions may not qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • the patient is communicating in the Finnish or English language
- • a deep primary or secondary carious lesion in 1st or 2nd premolar or molar on occlusal or proximal surface, extending to the deepest quarter of dentine assessed from the radiograph
- • asymptomatic or symptoms not more severe than reversible pulpitis (mild pulpitis according to the new pulpitis classification proposal)
- • pulp responding to the electric pulp testing and cold testing
- • the periodontal stage of the tooth should be I or II.
- • In case the patient has several teeth fulfilling the inclusion criteria, the one with the deepest lesion and/or most severe symptoms is chosen to the study.
- Exclusion Criteria:
- • general medical condition which makes the patient more susceptible to odontogenic infection complications
- • pregnancy, breastfeeding
- • mental retardation, memory disorder
- • the carious lesion is extending to more than three surfaces or to both proximal surfaces
- • the tooth has previous other filling(s): i) extending deeper than to the outer third of dentine; or ii) the filling is larger than Class I or II; or iii) Class II filling is not restricted to enamel; or iv) the filling has secondary/residual caries
- • the tooth is not restorable
- • periapical changes in the periapical radiograph
- • sensitivity to percussion; swelling; sinus tract; increased mobility; resorption
- • furcal lesion more severe than Class I
- • ongoing orthodontic treatment
- • declining to sign the written consent.
About University Of Helsinki
The University of Helsinki, a prestigious institution in Finland, is dedicated to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university engages in cutting-edge studies that aim to improve patient outcomes and contribute to the global knowledge base in medicine. Its commitment to ethical standards and rigorous methodology ensures the integrity and reliability of its clinical research initiatives, making it a key player in the development of novel therapeutic strategies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Espoo, , Finland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials